2024-01-02 19:54:49 | ERROR | stderr | /home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/site-packages/gradio/components/button.py:89: UserWarning: Using the update method is deprecated. Simply return a new object instead, e.g. `return gr.Button(...)` instead of `return gr.Button.update(...)`.
2024-01-02 19:54:49 | ERROR | stderr |   warnings.warn(
2024-01-02 19:54:49 | INFO | gradio_web_server | args: Namespace(host='0.0.0.0', port=None, share=True, controller_url='http://localhost:21001', concurrency_count=10, model_list_mode='once', moderate=False, show_terms_of_use=False, add_chatgpt=False, add_claude=False, add_palm=False, register_openai_compatible_models=None, gradio_auth_path=None, gradio_root_path=None)
2024-01-02 19:54:49 | INFO | gradio_web_server | Models: ['meditron-7b']
2024-01-02 19:54:49 | INFO | stdout | Running on local URL:  http://0.0.0.0:7860
2024-01-02 19:54:53 | INFO | stdout | Running on public URL: https://86f46050fc7b1c8c9d.gradio.live
2024-01-02 19:54:53 | INFO | stdout | 
2024-01-02 19:54:53 | INFO | stdout | This share link expires in 72 hours. For free permanent hosting and GPU upgrades, run `gradio deploy` from Terminal to deploy to Spaces (https://huggingface.co/spaces)
2024-01-02 19:55:00 | INFO | gradio_web_server | load_demo. ip: 172.31.46.135. params: {}
2024-01-02 19:55:00 | ERROR | stderr | /home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/site-packages/gradio/components/dropdown.py:176: UserWarning: Using the update method is deprecated. Simply return a new object instead, e.g. `return gr.Dropdown(...)` instead of `return gr.Dropdown.update(...)`.
2024-01-02 19:55:00 | ERROR | stderr |   warnings.warn(
2024-01-02 19:55:35 | INFO | gradio_web_server | add_text. ip: 172.31.46.135. len: 3
2024-01-02 19:55:35 | ERROR | stderr | /home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/asyncio/events.py:80: GradioUnusedKwargWarning: You have unused kwarg parameters in Button, please remove them: {'mode': 'static'}
2024-01-02 19:55:35 | ERROR | stderr |   self._context.run(self._callback, *self._args)
2024-01-02 19:55:35 | INFO | gradio_web_server | bot_response. ip: 172.31.46.135
2024-01-02 19:55:35 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 19:55:35 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: Hi!\n### Assistant:", 'temperature': 0.7, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 1024, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 19:55:41 | ERROR | stderr | /home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/asyncio/events.py:80: GradioUnusedKwargWarning: You have unused kwarg parameters in Button, please remove them: {'mode': 'dynamic'}
2024-01-02 19:55:41 | ERROR | stderr |   self._context.run(self._callback, *self._args)
2024-01-02 19:55:41 | INFO | gradio_web_server | Hi!

Is the weather supposed to be this hot?
2024-01-02 19:55:56 | INFO | gradio_web_server | add_text. ip: 172.31.46.135. len: 52
2024-01-02 19:55:56 | INFO | gradio_web_server | bot_response. ip: 172.31.46.135
2024-01-02 19:55:56 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 19:55:56 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: Hi!\n### Assistant: Hi!\n\nIs the weather supposed to be this hot?\n### User: Can you tell me about biomarkers in cancer research?\n### Assistant:", 'temperature': 0.7, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 1024, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 19:56:06 | INFO | gradio_web_server | Biomarkers are molecular markers in the human body that can be used to identify, diagnose, and predict prognosis of disease.
2024-01-02 19:56:35 | INFO | gradio_web_server | clear_history. ip: 172.31.46.135
2024-01-02 20:10:34 | INFO | gradio_web_server | add_text. ip: 172.31.21.150. len: 80
2024-01-02 20:10:35 | INFO | gradio_web_server | bot_response. ip: 172.31.21.150
2024-01-02 20:10:35 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:10:35 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: If I provide some text, can you try to identify the cancer biomarkers within it?\n### Assistant:", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:10:40 | INFO | gradio_web_server | Yes, I can try to identify the cancer biomarkers within it.
2024-01-02 20:10:59 | INFO | gradio_web_server | add_text. ip: 172.31.21.150. len: 667
2024-01-02 20:10:59 | INFO | gradio_web_server | bot_response. ip: 172.31.21.150
2024-01-02 20:10:59 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:10:59 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: If I provide some text, can you try to identify the cancer biomarkers within it?\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3...\n### Assistant:", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:11:06 | INFO | gradio_web_server | Yes, I can try to identify the cancer biomarkers within it.
2024-01-02 20:11:20 | INFO | gradio_web_server | add_text. ip: 172.31.21.150. len: 42
2024-01-02 20:11:20 | INFO | gradio_web_server | bot_response. ip: 172.31.21.150
2024-01-02 20:11:20 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:11:20 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: If I provide some text, can you try to identify the cancer biomarkers within it?\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3...\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: What are the biomarkers in the above text>\n### Assistant:", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:11:41 | INFO | gradio_web_server | The biomarkers in the above text are RET-fusion post-progression on selective RET inhibitor, NTRK fusion, MET overexpression, amplification, or mutation, AXL overexpression, amplification, or mutation, and ROS1 fusion.
2024-01-02 20:13:19 | INFO | gradio_web_server | add_text. ip: 172.31.46.135. len: 89
2024-01-02 20:13:19 | INFO | gradio_web_server | bot_response. ip: 172.31.46.135
2024-01-02 20:13:19 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:13:19 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: If I provide some text, can you try to identify the cancer biomarkers within it?\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3...\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: What are the biomarkers in the above text>\n### Assistant: The biomarkers in the above text are RET-fusion post-progression on selective RET inhibitor, NTRK fusion, MET overexpression, amplification, or mutation, AXL overexpression, amplification, or mutation, and ROS1 fusion.\n### User: Yes, that is almost correct. The only one you missed is KIF5B/RET Fusion Gene. Thank you.\n### Assistant:", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:13:23 | INFO | gradio_web_server | I am sorry, I did not know that.
2024-01-02 20:14:11 | INFO | gradio_web_server | add_text. ip: 172.31.46.135. len: 1196
2024-01-02 20:14:11 | INFO | gradio_web_server | bot_response. ip: 172.31.46.135
2024-01-02 20:14:11 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:14:11 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: If I provide some text, can you try to identify the cancer biomarkers within it?\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3...\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: What are the biomarkers in the above text>\n### Assistant: The biomarkers in the above text are RET-fusion post-progression on selective RET inhibitor, NTRK fusion, MET overexpression, amplification, or mutation, AXL overexpression, amplification, or mutation, and ROS1 fusion.\n### User: Yes, that is almost correct. The only one you missed is KIF5B/RET Fusion Gene. Thank you.\n### Assistant: I am sorry, I did not know that.\n### User: Can you try again with this text?\nPatients must have evidence of disease progression prior to enrollment  \nAll patients must have received a prior platinum-based chemotherapy regimen for treatment of urothelial cancer and must now be considered refractory to platinum-based chemotherapy; patients may have received the platinum-containing regimen either in the peri-operative or metastatic setting; patients may have received any number of additional prior therapies, and may have received prior immune therapies  \nPatients must have tumor evidence of somatic genomic molecular alteration in EGFR, HER2, ERBB3, or ERBB4, from a test result generated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory; the tumor tissue sample used to generate the qualifying report must be from a muscle-invasive or higher stage urinary tract cancer specimen (metastatic tissue is also acceptable); final determination about whether a specific tissue source or molecular genomic finding meets criteria as a qualifying result rests with the central study principal investigator (PI); germline genomic findings will not be returned to patients  \nPatients must be 18 years of age or older...\n### Assistant:", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:14:18 | INFO | gradio_web_server | Yes, I can try to identify the cancer biomarkers within it.
2024-01-02 20:14:25 | INFO | gradio_web_server | add_text. ip: 172.31.14.232. len: 20
2024-01-02 20:14:26 | INFO | gradio_web_server | bot_response. ip: 172.31.14.232
2024-01-02 20:14:26 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:14:26 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: If I provide some text, can you try to identify the cancer biomarkers within it?\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3...\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: What are the biomarkers in the above text>\n### Assistant: The biomarkers in the above text are RET-fusion post-progression on selective RET inhibitor, NTRK fusion, MET overexpression, amplification, or mutation, AXL overexpression, amplification, or mutation, and ROS1 fusion.\n### User: Yes, that is almost correct. The only one you missed is KIF5B/RET Fusion Gene. Thank you.\n### Assistant: I am sorry, I did not know that.\n### User: Can you try again with this text?\nPatients must have evidence of disease progression prior to enrollment  \nAll patients must have received a prior platinum-based chemotherapy regimen for treatment of urothelial cancer and must now be considered refractory to platinum-based chemotherapy; patients may have received the platinum-containing regimen either in the peri-operative or metastatic setting; patients may have received any number of additional prior therapies, and may have received prior immune therapies  \nPatients must have tumor evidence of somatic genomic molecular alteration in EGFR, HER2, ERBB3, or ERBB4, from a test result generated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory; the tumor tissue sample used to generate the qualifying report must be from a muscle-invasive or higher stage urinary tract cancer specimen (metastatic tissue is also acceptable); final determination about whether a specific tissue source or molecular genomic finding meets criteria as a qualifying result rests with the central study principal investigator (PI); germline genomic findings will not be returned to patients  \nPatients must be 18 years of age or older...\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: Okay, what are they?\n### Assistant:", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:14:36 | INFO | gradio_web_server | The biomarkers in the above text are EGFR, HER2, ERBB3, and ERBB4.
2024-01-02 20:18:16 | INFO | gradio_web_server | add_text. ip: 172.31.21.150. len: 1674
2024-01-02 20:18:17 | INFO | gradio_web_server | bot_response. ip: 172.31.21.150
2024-01-02 20:18:17 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:18:17 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: If I provide some text, can you try to identify the cancer biomarkers within it?\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3...\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: What are the biomarkers in the above text>\n### Assistant: The biomarkers in the above text are RET-fusion post-progression on selective RET inhibitor, NTRK fusion, MET overexpression, amplification, or mutation, AXL overexpression, amplification, or mutation, and ROS1 fusion.\n### User: Yes, that is almost correct. The only one you missed is KIF5B/RET Fusion Gene. Thank you.\n### Assistant: I am sorry, I did not know that.\n### User: Can you try again with this text?\nPatients must have evidence of disease progression prior to enrollment  \nAll patients must have received a prior platinum-based chemotherapy regimen for treatment of urothelial cancer and must now be considered refractory to platinum-based chemotherapy; patients may have received the platinum-containing regimen either in the peri-operative or metastatic setting; patients may have received any number of additional prior therapies, and may have received prior immune therapies  \nPatients must have tumor evidence of somatic genomic molecular alteration in EGFR, HER2, ERBB3, or ERBB4, from a test result generated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory; the tumor tissue sample used to generate the qualifying report must be from a muscle-invasive or higher stage urinary tract cancer specimen (metastatic tissue is also acceptable); final determination about whether a specific tissue source or molecular genomic finding meets criteria as a qualifying result rests with the central study principal investigator (PI); germline genomic findings will not be returned to patients  \nPatients must be 18 years of age or older...\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: Okay, what are they?\n### Assistant: The biomarkers in the above text are EGFR, HER2, ERBB3, and ERBB4.\n### User: What about in this text?\nPatients must have undergone complete surgical resection of their stage IIA, IIB, IIIA or IIIB non-squamous or squamous b NSCLC per American Joint Committee on Cancer (AJCC) 8th edition and have had negative margins. N3 disease is not allowed.  \nBaseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease  \nEastern Cooperative Oncology Group (ECOG) performance status 0 or 1  \nPatients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization  \nPositive for translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as defined by a Clinical Laboratory Improvement Act (CLIA)-approved test including: (1) translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as determined by the Vysis Break Point fluorescence in situ hybridization (FISH) assay; (2) ALK protein expression by immunohistochemistry (IHC); or (3) ALK rearrangement identified by next generation (NextGen) sequencing; this must have been performed:\n* By a local CLIA certified laboratory: Report must indicate the results as well as the CLIA number of the laboratory which performed the assay; tissue must be available for submission for central, retrospective confirmation of the ALK fusion status via ALCHEMIST-SCREEN (ALLIANCE A151216); OR\n* Patient registered to and the ALK fusion status performed centrally on the ALCHEMIST-SCREEN (ALLIANCE A151216)...\n### Assistant:", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:18:23 | INFO | gradio_web_server | Yes, I can try to identify the cancer biomarkers within it.
2024-01-02 20:18:28 | INFO | gradio_web_server | add_text. ip: 172.31.21.150. len: 20
2024-01-02 20:18:28 | INFO | gradio_web_server | bot_response. ip: 172.31.21.150
2024-01-02 20:18:28 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:18:28 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: If I provide some text, can you try to identify the cancer biomarkers within it?\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3...\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: What are the biomarkers in the above text>\n### Assistant: The biomarkers in the above text are RET-fusion post-progression on selective RET inhibitor, NTRK fusion, MET overexpression, amplification, or mutation, AXL overexpression, amplification, or mutation, and ROS1 fusion.\n### User: Yes, that is almost correct. The only one you missed is KIF5B/RET Fusion Gene. Thank you.\n### Assistant: I am sorry, I did not know that.\n### User: Can you try again with this text?\nPatients must have evidence of disease progression prior to enrollment  \nAll patients must have received a prior platinum-based chemotherapy regimen for treatment of urothelial cancer and must now be considered refractory to platinum-based chemotherapy; patients may have received the platinum-containing regimen either in the peri-operative or metastatic setting; patients may have received any number of additional prior therapies, and may have received prior immune therapies  \nPatients must have tumor evidence of somatic genomic molecular alteration in EGFR, HER2, ERBB3, or ERBB4, from a test result generated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory; the tumor tissue sample used to generate the qualifying report must be from a muscle-invasive or higher stage urinary tract cancer specimen (metastatic tissue is also acceptable); final determination about whether a specific tissue source or molecular genomic finding meets criteria as a qualifying result rests with the central study principal investigator (PI); germline genomic findings will not be returned to patients  \nPatients must be 18 years of age or older...\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: Okay, what are they?\n### Assistant: The biomarkers in the above text are EGFR, HER2, ERBB3, and ERBB4.\n### User: What about in this text?\nPatients must have undergone complete surgical resection of their stage IIA, IIB, IIIA or IIIB non-squamous or squamous b NSCLC per American Joint Committee on Cancer (AJCC) 8th edition and have had negative margins. N3 disease is not allowed.  \nBaseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease  \nEastern Cooperative Oncology Group (ECOG) performance status 0 or 1  \nPatients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization  \nPositive for translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as defined by a Clinical Laboratory Improvement Act (CLIA)-approved test including: (1) translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as determined by the Vysis Break Point fluorescence in situ hybridization (FISH) assay; (2) ALK protein expression by immunohistochemistry (IHC); or (3) ALK rearrangement identified by next generation (NextGen) sequencing; this must have been performed:\n* By a local CLIA certified laboratory: Report must indicate the results as well as the CLIA number of the laboratory which performed the assay; tissue must be available for submission for central, retrospective confirmation of the ALK fusion status via ALCHEMIST-SCREEN (ALLIANCE A151216); OR\n* Patient registered to and the ALK fusion status performed centrally on the ALCHEMIST-SCREEN (ALLIANCE A151216)...\n### Assistant: Yes, I can try to identify the cancer biomarkers within it.\n### User: Okay, what are they?\n### Assistant:", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:18:39 | INFO | gradio_web_server | The biomarkers in the above text are EGFR, HER2, ERBB3, and ERBB4.
2024-01-02 20:18:56 | INFO | gradio_web_server | clear_history. ip: 172.31.21.150
2024-01-02 20:19:30 | INFO | gradio_web_server | add_text. ip: 172.31.50.169. len: 1716
2024-01-02 20:19:31 | INFO | gradio_web_server | bot_response. ip: 172.31.50.169
2024-01-02 20:19:31 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:19:31 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': 'You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don\'t know the answer to a question, please don\'t share false information.\n### User: What are the biomarkers in this text (separated by "----"):\n----\nPatients must have undergone complete surgical resection of their stage IIA, IIB, IIIA or IIIB non-squamous or squamous b NSCLC per American Joint Committee on Cancer (AJCC) 8th edition and have had negative margins. N3 disease is not allowed.  \nBaseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease  \nEastern Cooperative Oncology Group (ECOG) performance status 0 or 1  \nPatients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization  \nPositive for translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as defined by a Clinical Laboratory Improvement Act (CLIA)-approved test including: (1) translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as determined by the Vysis Break Point fluorescence in situ hybridization (FISH) assay; (2) ALK protein expression by immunohistochemistry (IHC); or (3) ALK rearrangement identified by next generation (NextGen) sequencing; this must have been performed:\n* By a local CLIA certified laboratory: Report must indicate the results as well as the CLIA number of the laboratory which performed the assay; tissue must be available for submission for central, retrospective confirmation of the ALK fusion status via ALCHEMIST-SCREEN (ALLIANCE A151216); OR\n* Patient registered to and the ALK fusion status performed centrally on the ALCHEMIST-SCREEN (ALLIANCE A151216)\n----\n### Assistant:', 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:19:33 | INFO | gradio_web_server | ----
2024-01-02 20:19:39 | INFO | gradio_web_server | clear_history. ip: 172.31.50.169
2024-01-02 20:20:07 | INFO | gradio_web_server | add_text. ip: 172.31.50.169. len: 1698
2024-01-02 20:20:08 | INFO | gradio_web_server | bot_response. ip: 172.31.50.169
2024-01-02 20:20:08 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:20:08 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': 'You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don\'t know the answer to a question, please don\'t share false information.\n### User: What are the biomarkers in the following text:\n"Patients must have undergone complete surgical resection of their stage IIA, IIB, IIIA or IIIB non-squamous or squamous b NSCLC per American Joint Committee on Cancer (AJCC) 8th edition and have had negative margins. N3 disease is not allowed.  \nBaseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease  \nEastern Cooperative Oncology Group (ECOG) performance status 0 or 1  \nPatients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization  \nPositive for translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as defined by a Clinical Laboratory Improvement Act (CLIA)-approved test including: (1) translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as determined by the Vysis Break Point fluorescence in situ hybridization (FISH) assay; (2) ALK protein expression by immunohistochemistry (IHC); or (3) ALK rearrangement identified by next generation (NextGen) sequencing; this must have been performed:\n* By a local CLIA certified laboratory: Report must indicate the results as well as the CLIA number of the laboratory which performed the assay; tissue must be available for submission for central, retrospective confirmation of the ALK fusion status via ALCHEMIST-SCREEN (ALLIANCE A151216); OR\n* Patient registered to and the ALK fusion status performed centrally on the ALCHEMIST-SCREEN (ALLIANCE A151216)..."\n### Assistant:', 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:21:27 | INFO | gradio_web_server | The biomarkers in the following text are:
"Patients must have undergone complete surgical resection of their stage IIA, IIB, IIIA or IIIB non-squamous or squamous b NSCLC per American Joint Committee on Cancer (AJCC) 8th edition and have had negative margins. N3 disease is not allowed.  
Baseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease  
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1  
Patients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization  
Positive for translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as defined by a Clinical Laboratory Improvement Act (CLIA)-approved test including: (1) translocation
2024-01-02 20:25:56 | INFO | gradio_web_server | clear_history. ip: 172.31.46.135
2024-01-02 20:27:00 | INFO | gradio_web_server | add_text. ip: 172.31.50.169. len: 609
2024-01-02 20:27:01 | INFO | gradio_web_server | bot_response. ip: 172.31.50.169
2024-01-02 20:27:01 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:27:01 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: I have an example Markdown table that lists clinical trial eligibility criteria broken down by disease, biomarker, and prior therapy. Here it is:\n| criterion text | disease | biomarker | prior therapy |\n| ---- | ---- | ---- | ---- |\n| Patient must not have received prior radiation | | | radiotherapy |\n| Subject must have invasive ductal breast cancer with HER2 over-expression in the tumor tissue. | Invasive Ductal Breast Carcinoma | HER2 Positive, HER2 Over-expression | radiotherapy |\n| Subject must not have any affected lymph nodes or metastatic disease | Lymph node-Metastases Metastatic Disease | | |\n### Assistant:", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:27:39 | INFO | gradio_web_server | You are a helpful, respectful and honest assistant.
Always answer as helpfully as possible, while being safe.
Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.
Please ensure that your responses are socially unbiased and positive in nature.

If a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.
If you don't know the answer to a question, please don't share false information.
2024-01-02 20:29:04 | INFO | gradio_web_server | add_text. ip: 172.31.14.232. len: 2913
2024-01-02 20:29:05 | INFO | gradio_web_server | bot_response. ip: 172.31.14.232
2024-01-02 20:29:05 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:29:05 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: I have an example Markdown table that lists clinical trial eligibility criteria broken down by disease, biomarker, and prior therapy. Here it is:\n| criterion text | disease | biomarker | prior therapy |\n| ---- | ---- | ---- | ---- |\n| Patient must not have received prior radiation | | | radiotherapy |\n| Subject must have invasive ductal breast cancer with HER2 over-expression in the tumor tissue. | Invasive Ductal Breast Carcinoma | HER2 Positive, HER2 Over-expression | radiotherapy |\n| Subject must not have any affected lymph nodes or metastatic disease | Lymph node-Metastases Metastatic Disease | | |\n### Assistant: You are a helpful, respectful and honest assistant.\nAlways answer as helpfully as possible, while being safe.\nYour answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.\nPlease ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.\nIf you don't know the answer to a question, please don't share false information.\n### User: Can you put the following criteria in a table like the one from above?\n\nThe subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3  \nHemoglobin >= 9 g/dL  \nBilirubin =< 1.5 x the upper limit of normal (ULN); for subjects with known Gilbert's disease, bilirubin =< 3.0 mg/dL  \nSerum creatinine =< 1.5 x ULN, or creatinine clearance (CrCl) >= 30 mL/min; for creatinine clearance estimation, the Cockcroft and Gault equation should be used  \nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvement  \nUrine protein/creatinine ratio (UPCR) =< 1 mg/mg (113.2 mg/mmol) creatinine or 24-hour (hr) urine protein of < 1 g  \nSerum phosphorus, magnesium, and potassium >= lower limit of normal (LLN) after adequate supplementation if necessary  \nThe subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document  \nSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control; women of childbearing potential must have a negative pregnancy test at screening  \nWomen of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal; postmenopause is defined as amenorrhea >= 12 consecutive months; Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason  \nAny type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter; subjects on luteinizing-hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agents  \nPrior treatment with cabozantinib\n### Assistant:", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:29:32 | INFO | gradio_web_server | add_text. ip: 172.31.14.232. len: 3
2024-01-02 20:29:33 | INFO | gradio_web_server | bot_response. ip: 172.31.14.232
2024-01-02 20:29:33 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:29:33 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: I have an example Markdown table that lists clinical trial eligibility criteria broken down by disease, biomarker, and prior therapy. Here it is:\n| criterion text | disease | biomarker | prior therapy |\n| ---- | ---- | ---- | ---- |\n| Patient must not have received prior radiation | | | radiotherapy |\n| Subject must have invasive ductal breast cancer with HER2 over-expression in the tumor tissue. | Invasive Ductal Breast Carcinoma | HER2 Positive, HER2 Over-expression | radiotherapy |\n| Subject must not have any affected lymph nodes or metastatic disease | Lymph node-Metastases Metastatic Disease | | |\n### Assistant: You are a helpful, respectful and honest assistant.\nAlways answer as helpfully as possible, while being safe.\nYour answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.\nPlease ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.\nIf you don't know the answer to a question, please don't share false information.\n### User: Can you put the following criteria in a table like the one from above?\n\nThe subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3  \nHemoglobin >= 9 g/dL  \nBilirubin =< 1.5 x the upper limit of normal (ULN); for subjects with known Gilbert's disease, bilirubin =< 3.0 mg/dL  \nSerum creatinine =< 1.5 x ULN, or creatinine clearance (CrCl) >= 30 mL/min; for creatinine clearance estimation, the Cockcroft and Gault equation should be used  \nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvement  \nUrine protein/creatinine ratio (UPCR) =< 1 mg/mg (113.2 mg/mmol) creatinine or 24-hour (hr) urine protein of < 1 g  \nSerum phosphorus, magnesium, and potassium >= lower limit of normal (LLN) after adequate supplementation if necessary  \nThe subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document  \nSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control; women of childbearing potential must have a negative pregnancy test at screening  \nWomen of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal; postmenopause is defined as amenorrhea >= 12 consecutive months; Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason  \nAny type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter; subjects on luteinizing-hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agents  \nPrior treatment with cabozantinib\n### Assistant: You are a helpful, respectful and honest assistant.\nAlways answer as helpfully as possible, while being safe.\nYour answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.\nPlease ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or\n### User: Hi!\n### Assistant: You are a helpful, respectful and honest assistant.\nAlways answer as helpfully as possible, while being safe.\nYour answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.\nPlease ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not\n### ", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:29:55 | INFO | stdout | Keyboard interruption in main thread... closing server.
2024-01-02 20:29:55 | INFO | stdout | Killing tunnel 0.0.0.0:7860 <> https://86f46050fc7b1c8c9d.gradio.live
2024-01-02 20:32:34 | ERROR | stderr | /home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/site-packages/gradio/components/button.py:89: UserWarning: Using the update method is deprecated. Simply return a new object instead, e.g. `return gr.Button(...)` instead of `return gr.Button.update(...)`.
2024-01-02 20:32:34 | ERROR | stderr |   warnings.warn(
2024-01-02 20:32:34 | INFO | gradio_web_server | args: Namespace(host='0.0.0.0', port=None, share=True, controller_url='http://localhost:21001', concurrency_count=10, model_list_mode='once', moderate=False, show_terms_of_use=False, add_chatgpt=False, add_claude=False, add_palm=False, register_openai_compatible_models=None, gradio_auth_path=None, gradio_root_path=None)
2024-01-02 20:32:34 | INFO | gradio_web_server | Models: ['meditron-7b']
2024-01-02 20:32:34 | INFO | stdout | Running on local URL:  http://0.0.0.0:7860
2024-01-02 20:32:39 | INFO | stdout | Running on public URL: https://843a4c1d330fdbff3e.gradio.live
2024-01-02 20:32:39 | INFO | stdout | 
2024-01-02 20:32:39 | INFO | stdout | This share link expires in 72 hours. For free permanent hosting and GPU upgrades, run `gradio deploy` from Terminal to deploy to Spaces (https://huggingface.co/spaces)
2024-01-02 20:32:44 | INFO | gradio_web_server | load_demo. ip: 172.31.50.169. params: {}
2024-01-02 20:32:44 | ERROR | stderr | /home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/site-packages/gradio/components/dropdown.py:176: UserWarning: Using the update method is deprecated. Simply return a new object instead, e.g. `return gr.Dropdown(...)` instead of `return gr.Dropdown.update(...)`.
2024-01-02 20:32:44 | ERROR | stderr |   warnings.warn(
2024-01-02 20:33:31 | INFO | gradio_web_server | add_text. ip: 172.31.50.169. len: 124
2024-01-02 20:33:31 | ERROR | stderr | /home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/asyncio/events.py:80: GradioUnusedKwargWarning: You have unused kwarg parameters in Button, please remove them: {'mode': 'static'}
2024-01-02 20:33:31 | ERROR | stderr |   self._context.run(self._callback, *self._args)
2024-01-02 20:33:31 | INFO | gradio_web_server | bot_response. ip: 172.31.50.169
2024-01-02 20:33:31 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:33:31 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: I have a Markdown table that lists clinical trial eligibility criteria broken down by disease, biomarker, and prior therapy.\n### Assistant:", 'temperature': 0.7, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 1024, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:33:38 | ERROR | stderr | /home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/asyncio/events.py:80: GradioUnusedKwargWarning: You have unused kwarg parameters in Button, please remove them: {'mode': 'dynamic'}
2024-01-02 20:33:38 | ERROR | stderr |   self._context.run(self._callback, *self._args)
2024-01-02 20:33:38 | INFO | gradio_web_server | Please search for the disease name, biomarker, and prior therapy.
2024-01-02 20:33:51 | INFO | gradio_web_server | add_text. ip: 172.31.46.135. len: 490
2024-01-02 20:33:52 | INFO | gradio_web_server | bot_response. ip: 172.31.46.135
2024-01-02 20:33:52 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:33:52 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: I have a Markdown table that lists clinical trial eligibility criteria broken down by disease, biomarker, and prior therapy.\n### Assistant: Please search for the disease name, biomarker, and prior therapy.\n### User: Here is the example table:\n| criterion text | disease | biomarker | prior therapy |\n| ---- | ---- | ---- | ---- |\n| Patient must not have received prior radiation | | | radiotherapy |\n| Subject must have invasive ductal breast cancer with HER2 over-expression in the tumor tissue. | Invasive Ductal Breast Carcinoma | HER2 Positive, HER2 Over-expression | radiotherapy |\n| Subject must not have any affected lymph nodes or metastatic disease | Lymph node-Metastases Metastatic Disease | | |\n### Assistant:", 'temperature': 0.7, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 1024, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:34:02 | INFO | gradio_web_server | Are you referring to the "invasive ductal breast cancer with HER2 over-expression in the tumor tissue" criterion?
2024-01-02 20:35:08 | INFO | gradio_web_server | add_text. ip: 172.31.14.232. len: 2946
2024-01-02 20:35:08 | INFO | gradio_web_server | bot_response. ip: 172.31.14.232
2024-01-02 20:35:08 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:35:08 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': 'You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don\'t know the answer to a question, please don\'t share false information.\n### User: I have a Markdown table that lists clinical trial eligibility criteria broken down by disease, biomarker, and prior therapy.\n### Assistant: Please search for the disease name, biomarker, and prior therapy.\n### User: Here is the example table:\n| criterion text | disease | biomarker | prior therapy |\n| ---- | ---- | ---- | ---- |\n| Patient must not have received prior radiation | | | radiotherapy |\n| Subject must have invasive ductal breast cancer with HER2 over-expression in the tumor tissue. | Invasive Ductal Breast Carcinoma | HER2 Positive, HER2 Over-expression | radiotherapy |\n| Subject must not have any affected lymph nodes or metastatic disease | Lymph node-Metastases Metastatic Disease | | |\n### Assistant: Are you referring to the "invasive ductal breast cancer with HER2 over-expression in the tumor tissue" criterion?\n### User: Using the above table as an example, can you abstract the following criteria text into a similar table?\n\nThe subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3  \nHemoglobin >= 9 g/dL  \nBilirubin =< 1.5 x the upper limit of normal (ULN); for subjects with known Gilbert\'s disease, bilirubin =< 3.0 mg/dL  \nSerum creatinine =< 1.5 x ULN, or creatinine clearance (CrCl) >= 30 mL/min; for creatinine clearance estimation, the Cockcroft and Gault equation should be used  \nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvement  \nUrine protein/creatinine ratio (UPCR) =< 1 mg/mg (113.2 mg/mmol) creatinine or 24-hour (hr) urine protein of < 1 g  \nSerum phosphorus, magnesium, and potassium >= lower limit of normal (LLN) after adequate supplementation if necessary  \nThe subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document  \nSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control; women of childbearing potential must have a negative pregnancy test at screening  \nWomen of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal; postmenopause is defined as amenorrhea >= 12 consecutive months; Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason  \nAny type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter; subjects on luteinizing-hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agents  \nPrior treatment with cabozantinib\n### Assistant:', 'temperature': 0.7, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 1024, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:35:14 | INFO | gradio_web_server | Are you referring to the "metastatic disease" criterion?
2024-01-02 20:35:39 | INFO | gradio_web_server | add_text. ip: 172.31.14.232. len: 60
2024-01-02 20:35:40 | INFO | gradio_web_server | bot_response. ip: 172.31.14.232
2024-01-02 20:35:40 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:35:40 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': 'You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don\'t know the answer to a question, please don\'t share false information.\n### User: I have a Markdown table that lists clinical trial eligibility criteria broken down by disease, biomarker, and prior therapy.\n### Assistant: Please search for the disease name, biomarker, and prior therapy.\n### User: Here is the example table:\n| criterion text | disease | biomarker | prior therapy |\n| ---- | ---- | ---- | ---- |\n| Patient must not have received prior radiation | | | radiotherapy |\n| Subject must have invasive ductal breast cancer with HER2 over-expression in the tumor tissue. | Invasive Ductal Breast Carcinoma | HER2 Positive, HER2 Over-expression | radiotherapy |\n| Subject must not have any affected lymph nodes or metastatic disease | Lymph node-Metastases Metastatic Disease | | |\n### Assistant: Are you referring to the "invasive ductal breast cancer with HER2 over-expression in the tumor tissue" criterion?\n### User: Using the above table as an example, can you abstract the following criteria text into a similar table?\n\nThe subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3  \nHemoglobin >= 9 g/dL  \nBilirubin =< 1.5 x the upper limit of normal (ULN); for subjects with known Gilbert\'s disease, bilirubin =< 3.0 mg/dL  \nSerum creatinine =< 1.5 x ULN, or creatinine clearance (CrCl) >= 30 mL/min; for creatinine clearance estimation, the Cockcroft and Gault equation should be used  \nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvement  \nUrine protein/creatinine ratio (UPCR) =< 1 mg/mg (113.2 mg/mmol) creatinine or 24-hour (hr) urine protein of < 1 g  \nSerum phosphorus, magnesium, and potassium >= lower limit of normal (LLN) after adequate supplementation if necessary  \nThe subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document  \nSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control; women of childbearing potential must have a negative pregnancy test at screening  \nWomen of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal; postmenopause is defined as amenorrhea >= 12 consecutive months; Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason  \nAny type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter; subjects on luteinizing-hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agents  \nPrior treatment with cabozantinib\n### Assistant: Are you referring to the "metastatic disease" criterion?\n### User: I am referring to any criterion that you are able to locate.\n### Assistant:', 'temperature': 0.7, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 1024, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:36:49 | INFO | gradio_web_server | Can you abstract the criteria text into the table below?

The subject has not received systemic anticancer therapy, including investigational therapies, within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter; subjects on luteinizing-hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agents  
Any type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter; subjects on luteinizing-hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agents  
Prior treatment with cabozantinib
2024-01-02 20:38:04 | INFO | gradio_web_server | clear_history. ip: 172.31.50.169
2024-01-02 20:42:38 | INFO | gradio_web_server | add_text. ip: 172.31.50.169. len: 121
2024-01-02 20:42:38 | INFO | gradio_web_server | bot_response. ip: 172.31.50.169
2024-01-02 20:42:38 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:42:38 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: What are some examples of clinical trial eligibility biomarkers, especially in regards to cancer-related clinical trials?\n### Assistant:", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:43:56 | INFO | gradio_web_server | Clinical trial eligibility biomarkers are used to determine whether a patient is eligible to participate in a clinical trial. They are used to identify patients who are likely to benefit from the treatment being tested in the trial.

Clinical trial eligibility biomarkers can be used to identify patients who are likely to respond to a particular treatment. For example, a clinical trial may use a biomarker to identify patients who have a specific type of cancer.

Clinical trial eligibility biomarkers can also be used to identify patients who are likely to experience side effects from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience severe side effects from a treatment.

Clinical trial eligibility biomarkers can also be used to identify patients who are likely to experience a serious adverse event from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience a serious adverse event from a treatment.

Clinical trial eligibility biomarkers can also be used to identify patients who are likely to experience
2024-01-02 20:44:56 | INFO | gradio_web_server | add_text. ip: 172.31.46.135. len: 119
2024-01-02 20:44:56 | INFO | gradio_web_server | bot_response. ip: 172.31.46.135
2024-01-02 20:44:56 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:44:56 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: What are some examples of clinical trial eligibility biomarkers, especially in regards to cancer-related clinical trials?\n### Assistant: Clinical trial eligibility biomarkers are used to determine whether a patient is eligible to participate in a clinical trial. They are used to identify patients who are likely to benefit from the treatment being tested in the trial.\n\nClinical trial eligibility biomarkers can be used to identify patients who are likely to respond to a particular treatment. For example, a clinical trial may use a biomarker to identify patients who have a specific type of cancer.\n\nClinical trial eligibility biomarkers can also be used to identify patients who are likely to experience side effects from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience severe side effects from a treatment.\n\nClinical trial eligibility biomarkers can also be used to identify patients who are likely to experience a serious adverse event from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience a serious adverse event from a treatment.\n\nClinical trial eligibility biomarkers can also be used to identify patients who are likely to experience\n### User: What are some examples of clinical trial eligibility diseases, especially in regards to cancer-related clinical trials?\n### Assistant:", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:46:13 | INFO | gradio_web_server | Clinical trial eligibility diseases are used to determine whether a patient is eligible to participate in a clinical trial. They are used to identify patients who are likely to benefit from the treatment being tested in the trial.

Clinical trial eligibility diseases can be used to identify patients who are likely to respond to a particular treatment. For example, a clinical trial may use a biomarker to identify patients who have a specific type of cancer.

Clinical trial eligibility diseases can also be used to identify patients who are likely to experience side effects from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience severe side effects from a treatment.

Clinical trial eligibility diseases can also be used to identify patients who are likely to experience a serious adverse event from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience a serious adverse event from a treatment.

Clinical trial eligibility diseases can also be used to identify patients who are likely to experience
2024-01-02 20:47:38 | INFO | gradio_web_server | add_text. ip: 172.31.46.135. len: 2974
2024-01-02 20:47:38 | INFO | gradio_web_server | bot_response. ip: 172.31.46.135
2024-01-02 20:47:38 | INFO | gradio_web_server | model_name: meditron-7b, worker_addr: http://localhost:21002
2024-01-02 20:47:38 | INFO | gradio_web_server | ==== request ====
{'model': 'meditron-7b', 'prompt': "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.\n### User: What are some examples of clinical trial eligibility biomarkers, especially in regards to cancer-related clinical trials?\n### Assistant: Clinical trial eligibility biomarkers are used to determine whether a patient is eligible to participate in a clinical trial. They are used to identify patients who are likely to benefit from the treatment being tested in the trial.\n\nClinical trial eligibility biomarkers can be used to identify patients who are likely to respond to a particular treatment. For example, a clinical trial may use a biomarker to identify patients who have a specific type of cancer.\n\nClinical trial eligibility biomarkers can also be used to identify patients who are likely to experience side effects from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience severe side effects from a treatment.\n\nClinical trial eligibility biomarkers can also be used to identify patients who are likely to experience a serious adverse event from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience a serious adverse event from a treatment.\n\nClinical trial eligibility biomarkers can also be used to identify patients who are likely to experience\n### User: What are some examples of clinical trial eligibility diseases, especially in regards to cancer-related clinical trials?\n### Assistant: Clinical trial eligibility diseases are used to determine whether a patient is eligible to participate in a clinical trial. They are used to identify patients who are likely to benefit from the treatment being tested in the trial.\n\nClinical trial eligibility diseases can be used to identify patients who are likely to respond to a particular treatment. For example, a clinical trial may use a biomarker to identify patients who have a specific type of cancer.\n\nClinical trial eligibility diseases can also be used to identify patients who are likely to experience side effects from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience severe side effects from a treatment.\n\nClinical trial eligibility diseases can also be used to identify patients who are likely to experience a serious adverse event from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience a serious adverse event from a treatment.\n\nClinical trial eligibility diseases can also be used to identify patients who are likely to experience\n### User: Based on your understanding of eligibility diseases and biomarkers, can you identify the diseases located in the following text?\n\nThe subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3  \nHemoglobin >= 9 g/dL  \nBilirubin =< 1.5 x the upper limit of normal (ULN); for subjects with known Gilbert's disease, bilirubin =< 3.0 mg/dL  \nSerum creatinine =< 1.5 x ULN, or creatinine clearance (CrCl) >= 30 mL/min; for creatinine clearance estimation, the Cockcroft and Gault equation should be used  \nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvement  \nUrine protein/creatinine ratio (UPCR) =< 1 mg/mg (113.2 mg/mmol) creatinine or 24-hour (hr) urine protein of < 1 g  \nSerum phosphorus, magnesium, and potassium >= lower limit of normal (LLN) after adequate supplementation if necessary  \nThe subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document  \nSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control; women of childbearing potential must have a negative pregnancy test at screening  \nWomen of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal; postmenopause is defined as amenorrhea >= 12 consecutive months; Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason  \nAny type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter; subjects on luteinizing-hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agents  \nPrior treatment with cabozantinib...\n### Assistant:", 'temperature': 0.1, 'repetition_penalty': 1.0, 'top_p': 1.0, 'max_new_tokens': 256, 'stop': ['<\\s>', '###', 'Assistant:', 'User:'], 'stop_token_ids': None, 'echo': False}
2024-01-02 20:48:30 | INFO | gradio_web_server | load_demo. ip: 172.31.46.135. params: {}
2024-01-02 20:48:45 | INFO | stdout | Keyboard interruption in main thread... closing server.
2024-01-02 20:48:51 | ERROR | stderr | Traceback (most recent call last):
2024-01-02 20:48:51 | ERROR | stderr |   File "/home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/site-packages/gradio/blocks.py", line 2361, in block_thread
2024-01-02 20:48:51 | ERROR | stderr |     time.sleep(0.1)
2024-01-02 20:48:51 | ERROR | stderr | KeyboardInterrupt
2024-01-02 20:48:51 | ERROR | stderr | 
2024-01-02 20:48:51 | ERROR | stderr | During handling of the above exception, another exception occurred:
2024-01-02 20:48:51 | ERROR | stderr | 
2024-01-02 20:48:51 | ERROR | stderr | Traceback (most recent call last):
2024-01-02 20:48:51 | ERROR | stderr |   File "/home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/runpy.py", line 196, in _run_module_as_main
2024-01-02 20:48:51 | ERROR | stderr |     return _run_code(code, main_globals, None,
2024-01-02 20:48:51 | ERROR | stderr |   File "/home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/runpy.py", line 86, in _run_code
2024-01-02 20:48:51 | ERROR | stderr |     exec(code, run_globals)
2024-01-02 20:48:51 | ERROR | stderr |   File "/home/ec2-user/SageMaker/FastChat/fastchat/serve/gradio_web_server.py", line 892, in <module>
2024-01-02 20:48:51 | ERROR | stderr |     demo.queue(
2024-01-02 20:48:51 | ERROR | stderr |   File "/home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/site-packages/gradio/blocks.py", line 2266, in launch
2024-01-02 20:48:51 | ERROR | stderr |     self.block_thread()
2024-01-02 20:48:51 | ERROR | stderr |   File "/home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/site-packages/gradio/blocks.py", line 2365, in block_thread
2024-01-02 20:48:51 | ERROR | stderr |     self.server.close()
2024-01-02 20:48:51 | ERROR | stderr |   File "/home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/site-packages/gradio/networking.py", line 75, in close
2024-01-02 20:48:51 | ERROR | stderr |     self.thread.join()
2024-01-02 20:48:51 | ERROR | stderr |   File "/home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/threading.py", line 1096, in join
2024-01-02 20:48:51 | ERROR | stderr |     self._wait_for_tstate_lock()
2024-01-02 20:48:51 | ERROR | stderr |   File "/home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/threading.py", line 1116, in _wait_for_tstate_lock
2024-01-02 20:48:51 | ERROR | stderr |     if lock.acquire(block, timeout):
2024-01-02 20:48:51 | ERROR | stderr | KeyboardInterrupt
2024-01-02 20:48:51 | INFO | stdout | Killing tunnel 0.0.0.0:7860 <> https://843a4c1d330fdbff3e.gradio.live
2024-01-02 20:48:59 | ERROR | stderr | /home/ec2-user/anaconda3/envs/JupyterSystemEnv/lib/python3.10/site-packages/gradio/components/button.py:89: UserWarning: Using the update method is deprecated. Simply return a new object instead, e.g. `return gr.Button(...)` instead of `return gr.Button.update(...)`.
2024-01-02 20:48:59 | ERROR | stderr |   warnings.warn(
2024-01-02 20:48:59 | INFO | stdout | usage: gradio_web_server.py [-h] [--host HOST] [--port PORT] [--share] [--controller-url CONTROLLER_URL] [--concurrency-count CONCURRENCY_COUNT]
2024-01-02 20:48:59 | INFO | stdout |                             [--model-list-mode {once,reload}] [--moderate] [--show-terms-of-use] [--add-chatgpt] [--add-claude] [--add-palm]
2024-01-02 20:48:59 | INFO | stdout |                             [--register-openai-compatible-models REGISTER_OPENAI_COMPATIBLE_MODELS] [--gradio-auth-path GRADIO_AUTH_PATH]
2024-01-02 20:48:59 | INFO | stdout |                             [--gradio-root-path GRADIO_ROOT_PATH]
2024-01-02 20:48:59 | INFO | stdout | 
2024-01-02 20:48:59 | INFO | stdout | options:
2024-01-02 20:48:59 | INFO | stdout |   -h, --help            show this help message and exit
2024-01-02 20:48:59 | INFO | stdout |   --host HOST
2024-01-02 20:48:59 | INFO | stdout |   --port PORT
2024-01-02 20:48:59 | INFO | stdout |   --share               Whether to generate a public, shareable link
2024-01-02 20:48:59 | INFO | stdout |   --controller-url CONTROLLER_URL
2024-01-02 20:48:59 | INFO | stdout |                         The address of the controller
2024-01-02 20:48:59 | INFO | stdout |   --concurrency-count CONCURRENCY_COUNT
2024-01-02 20:48:59 | INFO | stdout |                         The concurrency count of the gradio queue
2024-01-02 20:48:59 | INFO | stdout |   --model-list-mode {once,reload}
2024-01-02 20:48:59 | INFO | stdout |                         Whether to load the model list once or reload the model list every time
2024-01-02 20:48:59 | INFO | stdout |   --moderate            Enable content moderation to block unsafe inputs
2024-01-02 20:48:59 | INFO | stdout |   --show-terms-of-use   Shows term of use before loading the demo
2024-01-02 20:48:59 | INFO | stdout |   --add-chatgpt         Add OpenAI's ChatGPT models (gpt-3.5-turbo, gpt-4)
2024-01-02 20:48:59 | INFO | stdout |   --add-claude          Add Anthropic's Claude models (claude-2, claude-instant-1)
2024-01-02 20:48:59 | INFO | stdout |   --add-palm            Add Google's PaLM model (PaLM 2 for Chat: chat-bison@001)
2024-01-02 20:48:59 | INFO | stdout |   --register-openai-compatible-models REGISTER_OPENAI_COMPATIBLE_MODELS
2024-01-02 20:48:59 | INFO | stdout |                         Register custom OpenAI API compatible models by loading them from a JSON file
2024-01-02 20:48:59 | INFO | stdout |   --gradio-auth-path GRADIO_AUTH_PATH
2024-01-02 20:48:59 | INFO | stdout |                         Set the gradio authentication file path. The file should contain one or more user:password pairs in this format: "u1:p1,u2:p2,u3:p3"
2024-01-02 20:48:59 | INFO | stdout |   --gradio-root-path GRADIO_ROOT_PATH
2024-01-02 20:48:59 | INFO | stdout |                         Sets the gradio root path, eg /abc/def. Useful when running behind a reverse-proxy or at a custom URL path prefix
